Diabetic Nephropathy Market Information: By Diagnosis (Urine Test, Blood Test), By Treatment (Medications, Kidney Dialysis, Transplant), By Indication (Diabetes 1, Diabetes 2), By End User (Hospital & Clinic, Surgical Centers) - Global Forecast Till 2023

Synopsis of the Global Diabetic Nephropathy Market

Diabetic nephropathy, also known as diabetic kidney disease, is a kidney-related disease to type 1 and type 2 diabetes. This condition affects the normal functioning of the kidney and disturbs its ability to remove waste products and extra fluid from the body. Diabetes and high blood pressure are the major risk factors for diabetic nephropathy. Preventive care includes following a healthy lifestyle and proper monitoring and treatment of high blood pressure and diabetes. Early diagnosis and treatment help to reduce further damage to the kidney, thereby helping in disease management. If left untreated, it may lead to kidney failure, a severe and life-threatening condition.

Factors driving the growth of the market are rising prevalence of chronic diseases diabetes, obesity and increasing demand for diagnostic tests such as urine test, blood test, kidney biopsy, and imaging tests such as MRI and CT scan. As per the data by World Health Organization (WHO), chronic diseases account for nearly 59% of the mortality and death toll due to chronic disease is as high as 35 million across the globe. Furthermore, technological advancements in diagnostic imaging and increasing focus on early diagnosis of diseases also influence the market growth. The accuracy of a diagnostic test for the diagnosis of diabetic nephropathy and the high cost of imaging devices restrain the market growth. Significant growth of medical device industry and availability of cutting-edge technologies for diagnosis further stimulates the market growth.

Global diabetic nephropathy market is expected to grow at a CAGR of 5.2% during the forecast period.

Segments

The global diabetic nephropathy market is segmented on the basis of diagnosis, treatment, indication, and end user.

On the basis of diagnosis, the market is segmented into blood test, urine tests, imaging tests, renal function testing and kidney biopsy.

Imaging tests are further segmented into X-ray, CT, and MRI.

On the basis of treatment, the market is segmented into medications, kidney dialysis, and transplant.

Medications are further segmented into angiotensin-converting enzyme inhibitors angiotensin II receptor blockers, antioxidant inflammation modulator, renin inhibitors, diuretics, calcium channel blockers, g protein-coupled receptors, connective tissue growth factor inhibitors, monocyte chemoattractant proteins inhibitor, and endothelin-A receptor antagonist.

On the basis of indication, the market is segmented into Diabetes 1 and Diabetes 2.

On the basis of the end user, the market is segmented into hospital & clinics, diagnostic center, research institutes, and others.

**Intended Audience**
- Medical Device Manufacturers
- Medical Device Suppliers
- Medical Research Laboratories
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

**Research Methodology**

**Regional Analysis of the Global Diabetic Nephropathy Market**

America diabetic nephropathy is the largest across the globe and is driven by the extensive use of diagnostic tests, rising emphasis on diagnosis and continuous monitoring of diabetes and high blood pressure. Additionally, the prevalence of various kidney diseases is found to be increasing in the U.S. National Chronic Kidney Disease stated that Chronic Kidney Disease (CKD) is common among adults in the U.S. and 30 million people, or 15% of U.S. adults are expected to have chronic kidney disease.

Europe Diabetic Nephropathy market is driven by increasing demand for diagnostics services and growing emphasis on home diagnosis, especially for the geriatric population, with Germany being the largest market. Additionally, the emergence of new market players in medical devices market, thereby increasing competition also boost the market growth. Furthermore, a significant rise in investment for the development of new technologies for the treatment of diseases and favorable reimbursement policies will fuel the market growth during the forecast period.

In Asia Pacific, an alarming increase in the prevalence of chronic disease such as cardiovascular diseases, kidney disease, obesity, diabetes, especially among the geriatric population is a major factor driving the market growth. China and India have the largest diabetic population which is expected to increase drastically in the near future, thereby
accelerating the market growth. In India, there is a need to create awareness about diabetes and kidney disease and its diagnosis among the patients. Furthermore, lifestyle changes, sedentary lifestyle, and obesity also contribute to the rise in the prevalence of diabetes and cardiovascular disease.

The market in Middle East & Africa demonstrates steady progress with rising number of diagnostic services, and growing emphasis on diagnosis and treatment of kidney disease. Major economies contributing to the market growth are Saudi Arabia and United Arab Emirates (UAE), due to the availability of specialty healthcare services and rising usage of diagnostic devices.

**Key Players in the Global Diabetic Nephropathy Market**

Some of the key players in this market are Merck & Co., Inc. (U.S.), Bayer AG (Germany), Abbott (U.S.), Sanofi (France), Novartis AG (Switzerland), Reata Pharmaceuticals, Inc. (U.S.), Pfizer Inc. (U.S.), AbbVie Inc. (U.S.), Eli Lilly and Company (U.S.), General Electric Company (U.S.), Siemens AG (Germany), Mitsubishi Tanabe Pharma Corporation (Japan) and others.
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 Republic of Korea
10.4.6 Rest of Asia Pacific
10.5 The Middle East & Africa
10.5.1 United Arab Emirates
10.5.2 Saudi Arabia
10.5.3 Oman
10.5.4 Kuwait
10.5.5 Qatar
10.5.6 Rest of the Middle East & Africa

11 Company Landscape
11.1 Introduction
11.2 Market Share Analysis
11.3 Key Development & Strategies
11.3.1 Key Developments

12 Company Profiles
12.1 Bayer AG
12.1.1 Company Overview
12.1.2 Product Overview
12.1.3 Financials
12.2 Merck & Co., Inc.
12.2.1 Company Overview
12.2.2 Product Overview
12.2.3 Financial Overview
12.2.4 Key Developments
12.3 Novartis AG
12.3.1 Company Overview
12.3.2 Product Overview
12.3.3 Financial Overview
12.3.4 Key Development
12.4 Reata Pharmaceuticals, Inc.
12.4.1 Company Overview
12.4.2 Product/Business Segment Overview
12.4.3 Financial Overview
12.4.4 Key Development
12.5 Pfizer Inc.
12.5.1 Company Overview
12.5.2 Product Overview
12.5.3 Financial Overview
12.5.4 Key Developments
12.6 Abbott
12.6.1 Company Overview
12.6.2 Product Overview
12.6.3 Financial Overview
12.6.4 Key Developments
12.7 Sanofi
12.7.1 Overview
12.7.2 Product Overview
12.7.3 Financials
12.7.4 Key Developments
12.8 Others

13 MRFR Conclusion
13.1 Key Findings
13.1.1 From CEO’s View Point
13.1.2 Unmet Needs of the Market
13.2 Key Companies to Watch
13.3 Prediction of Healthcare Diagnostics Industry

14 Appendix

LIST OF TABLES
Table 1 Diabetic Nephropathy Industry Synopsis, 2017-2023
Table 2 Global Diabetic Nephropathy Market Estimates and Forecast, 2017-2023, (USD Million)
Table 3 Global Diabetic Nephropathy Market by Region, 2017-2023, (USD Million)
Table 4 Global Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 5 Global Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 6 Global Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 7 Global Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 8 North America Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 9 North America Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 10 North America Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 11 North America Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 12 US Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 13 US Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 14 US Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 15 US Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 16 Canada Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 17 Canada Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 18 Canada Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 19 Canada Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 20 South America Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 21 South America Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 22 South America Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 23 South America Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 24 Europe Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 25 Europe Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 26 Europe Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 27 Europe Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 28 Western Europe Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 29 Western Europe Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 30 Western Europe Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 31 Western Europe Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 32 Eastern Europe Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 33 Eastern Europe Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 34 Eastern Europe Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 35 Eastern Europe Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 36 Asia Pacific Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 37 Asia Pacific Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 38 Asia Pacific Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 39 Asia Pacific Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)
Table 40 Middle East & Africa Diabetic Nephropathy Market by Diagnosis, 2017-2023, (USD Million)
Table 41 Middle East & Africa Diabetic Nephropathy Market by Treatment, 2017-2023, (USD Million)
Table 42 Middle East & Africa Diabetic Nephropathy Market by Indication, 2017-2023, (USD Million)
Table 43 Middle East & Africa Diabetic Nephropathy Market by End Users, 2017-2023, (USD Million)

LIST OF FIGURES

Figure 1 Research Process
Figure 2 Segmentation for Global Diabetic Nephropathy Market
Figure 3 Segmentation Market Dynamics for Diabetic Nephropathy Market
Figure 4 Global Diabetic Nephropathy Market Share, by Treatment 2016
Figure 5 Global Diabetic Nephropathy Market Share, by Indication 2016
Figure 6 Global Diabetic Nephropathy Market Share, by End Users, 2016
Figure 7 Global Diabetic Nephropathy Market Share, by Region, 2016
Figure 8 North America Diabetic Nephropathy Market Share, by Country, 2016
Figure 9 Europe Diabetic Nephropathy Market Share, by Country, 2016
Figure 10 Asia Pacific Diabetic Nephropathy Market Share, by Country, 2016
Figure 11 Middle East & Africa Diabetic Nephropathy Market Share, by Country, 2016
Figure 12 Global Diabetic Nephropathy Market: Company Share Analysis, 2016 (%)
Figure 13 Bayer AG: Key Financials
Figure 14 Bayer AG: Segmental Revenue
Figure 16 Bayer AG: Geographical Revenue
Figure 17 Merck & Co., Inc.: Key Financials
Figure 18 Merck & Co., Inc.: Segmental Revenue
Figure 19 Merck & Co., Inc.: Geographical Revenue
Figure 20 Novartis AG: Key Financials
Figure 21 Novartis AG: Segmental Revenue
Figure 22 Novartis AG: Geographical Revenue
Figure 23 Reata Pharmaceuticals, Inc.: Key Financials
Figure 24 Reata Pharmaceuticals, Inc.: Segmental Revenue
Figure 25 Reata Pharmaceuticals, Inc.: Geographical Revenue
Figure 26 Abbott: Key Financials
Figure 27 Abbott: Segmental Revenue
Figure 28 Abbott: Geographical Revenue
Figure 29 Pfizer Inc.: Key Financials
Figure 30 Pfizer Inc.: Segmental Revenue
Figure 31 Pfizer Inc.: Geographical Revenue
Figure 32 Sanofi: Key Financials
Figure 33 Sanofi: Segmental Revenue
Figure 34 Sanofi: Geographical Revenue